KOL (Key Opinion Leader) mapping in oncology is the process of identifying KOLs (Key Opinion Leaders) and their networks that align with the brand’s scientific objective. That’s how the process is called KOL Mapping. KOL mapping is done to find and evaluate expert healthcare professionals, including clinicians, surgeons, clinical trial investigators, and academicians, who hold significant influence within their therapeutic area. These experts are engaged by life sciences organizations, including pharmaceutical, biotechnology, medical technology, and diagnostics companies to support research initiatives, scientific publications, and advocacy efforts.
But the oncology therapeutic area is vast, constantly evolving, and densely populated with researchers, clinicians, and investigators. Their influence spans multiple tumor types, treatment modalities, and geographies. For Medical Affairs teams in oncology, when it comes to engaging with the right KOLs, the KOL lists, which were relevant a year ago may not hold good now. They will need to update the list to engage KOLs whose influence and network is growing.
What It Takes to Build a Comprehensive Oncology KOL Profile
Building a comprehensive list of top oncologists or KOL mapping requires continuous tracking of various data points including:
- Publication activity — volume, recency, journal impact, and citation counts across relevant tumor types and treatment areas
- Clinical trial involvement — roles as Principal Investigator, Co-Investigator, or study contributor across active and completed trials
- Conference presence — presentations, poster sessions, and panel participation at major oncology congresses such as ASCO, ESMO, ASH, and AACR
- Guideline contributions — involvement in developing or updating treatment guidelines and consensus statements
- Digital footprint — activity across professional networks, medical platforms, and social media that shapes peer conversations
- Peer recognition — how frequently an expert is cited, referenced, or collaborated with by others in the field
Together, these data points form the foundation of a comprehensive KOL profile. Medical Affairs teams, including MSLs (Medical Science Liaisons), who are on field meeting physicians and specialists need evaluation of experts at this level to execute their objectives forward.
The Challenge of Prioritization in Oncology
Building a comprehensive list of top oncologists requires continuous tracking of publications, congress activity, trial participation, and institutional affiliations. Mapping KOLs for complete profiles and network connections is a rigorous process. It is largely manual, time-consuming, and prone to duplication and errors in profile compilation. Rectifying these takes another round of review, and all of this can delay engagement planning by weeks.
In oncology, where expert networks are large and frequently overlap across tumor types, treatment modalities, and functions, prioritization is where most Medical Affairs teams struggle. Not every identified expert is the right fit for every initiative. A publication strategy requires different expertise than a speaker program. An advisory board focused on early-stage drug development needs different voices than clinicians prescribing medicines.
Without a structured framework, teams tend to shortlist only the most visible names. The result is a list of experts that are already overengaged, while others whose influence may be equally significant but less prominent are consistently overlooked. Over time, this narrows the Medical Affairs team’s network and limits the quality of scientific exchange.
How a KOL Management Platform Transforms Oncology KOL Mapping
A KOL management platform simplifies this significantly. Powered by AI, the platform continuously crawls and analyses data points across publications, conference activity, clinical trial registries, and other publicly available sources to identify relevant experts in oncology. It validates this data, generates insights, and produces a ready-to-use list of KOLs along with their complete profiles, covering scientific output, therapeutic focus, institutional affiliations, and engagement history.
This removes the need for teams to manually track, compile, and verify expert data across multiple sources. The KOL management platform builds and updates profiles automatically, so Medical Affairs teams are always working with current information rather than a snapshot that may already be outdated. Platforms like konectar are built specifically for this — enabling life sciences teams to move from scattered data to structured KOL intelligence without the manual overhead.
Where the platform adds further value is in network mapping. Oncology experts rarely operate in isolation. A researcher active in immuno-oncology may also contribute to hematology trials, present at cross-specialty congresses, and collaborate with investigators across geographies. The KOL management platform surfaces these connections, giving teams a clearer picture of how influence flows across the oncology landscape and where the most relevant experts sit within it.
The result is a faster, more accurate foundation for KOL engagement — with less duplication, fewer errors, and more time for the work that actually matters.
Conclusion
Oncology KOL mapping is not a one-time exercise. As therapeutic landscape changes, new researchers emerge, and influence patterns evolve, life sciences teams will need to keep track of all these. A KOL management platform brings structure, speed, and accuracy to this process that has traditionally been resource-heavy and error-prone. From KOL identification to network mapping, it gives teams the insights they need to engage the right experts at the right time and build relationships that hold scientific and strategic value over the long term.
FAQs:
What is KOL mapping in oncology?
KOL mapping in oncology is the process of identifying, profiling, and analysing key opinion leaders across tumor types, treatment areas, and geographies to support Medical Affairs strategy.
Why is KOL mapping more complex in oncology than other therapy areas?
Oncology has a large and fragmented expert landscape. Researchers often span multiple tumor types and functions, influence shifts frequently, and new voices emerge regularly through trials and publications — making continuous tracking essential.
How does a KOL management platform support KOL mapping?
The platform automatically crawls different publications, trial registries, social media channels , etc to build complete KOL profiles, and update them continuously. It helps remove the manual effort involved in tracking and compiling data.
What is the difference between KOL identification and KOL mapping?
Identification is about finding relevant healthcare experts. Mapping goes further, including building KOLs’ complete profiles, understanding their networks, and analysing how influence connects across the oncology landscape.